About Oralight

Every innovation in healthcare begins with a problem that refuses to be solved the old way. For both adult and pediatric patients suffering from mucosal complications—especially those undergoing cancer treatment—the burden is real, painful, and often overlooked. We believe there is a better way.

Our company was founded by a multidisciplinary team of scientists, clinicians, and entrepreneurs who came together to rethink how Oral Mucositis is treated, using technology to deliver a therapy with consistency, accuracy, and outcomes clinicians can trust. Such precision medicine should not be optional—it should be the standard.

Our first innovation, an automated Photobiomodulation Therapy (PBM-T) system, redefines how light-based therapy is delivered. By removing variability and human error, we’ve created a platform that is personalized and enables reliable, repeatable, and highly effective treatment—setting a new benchmark for patient care.

But we’re just getting started. We are building a next generation combination therapy that integrates advanced antimicrobial technology with PBM-T, aiming to transform how Oral Mucositis is treated, and how supportive oncology care is delivered overall. Working alongside a leading cancer center, we are translating science into real-world clinical workflows that improve lives.

We are at the forefront of a future where mucosal complications no longer limit recovery, quality of life, or outcomes. Through innovation, collaboration, and relentless focus on patients, we are redefining what’s possible in supportive care.